Six patents currently held, every record listed here
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2034. from the record
Of the 2 now held by other companies, 1 name Bantam Pharmaceutical LLC as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2034
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2017 to 2043.
US 10,508,087
Crystalline Forms of Trisodium Supramolecular Complex Comprising Valsartan and AHU-377 and Methods Thereof
Dec 8, 2035
US 9,957,240
Crystalline Forms of Trisodium Supramolecular Complex Comprising Valsartan and AHU-377 and Methods Thereof
Dec 8, 2035
US 10,266,523
Crystaline Forms of N-[6-(CIS-2,6-Dimethylmorpholine -4-YL)PYRIDINE-3-YL]-2-Methyl-4'-(TRIFLUOROMETHOXY) [1,1'-Biphenyl]-3-Methanamide Monophosphate, and Process of Preparation Thereof
Mar 30, 2036
US 10,246,418
New Crystal Form of Lenvatinib Methanesulfonate Salt and Preparation Method Thereof
Jun 8, 2036
US 12,378,234
Crystalline Polymorphs of a 1-Thiazol-2-YL-PYRAZOLE-5-Carboxylic Acid Derivative
Jun 2, 2042
US 12,673,955
New Crystal Form of P-Toluenesulfonate Salt of Diazabicyclic Compound and Preparation Method Therefor
Jul 30, 2043
202220272032203720422043
1 pending application: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2034 · High confidence
Also notable
Ends Dec 2035 · High confidence
Also notable
Ends Jul 2043 · High confidence
Crystalline Form I of Ibrutinib
US 9,751,889
The most cited patent in this portfolio, cited by 17 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2034.
Salt of Pyrrolo[2,3-d]pyrimidine Compound and Novel Polymorph of Salt
US 10,138,250
Granted 2018. Computed term ends 2035. A terminal disclaimer caps this term to an earlier patent's.
New Crystal Form of P-Toluenesulfonate Salt of Diazabicyclic Compound and Preparation Method Therefor
US 12,673,955
Granted 2026. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Mar 2036 · High confidence
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
now held by Sun Pharmaceutical Industries Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 17, 2027The maintenance fee for Crystalline Forms of Trisodium Supramolecular Complex Comprising Valsartan and AHU-377 and Methods Thereof (US 10,508,087) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Crystalline Form I of Ibrutinib | 4 in force | to Jun 2036 |
| New Crystal Form of P-Toluenesulfonate Salt of Diazabicyclic Compound and Preparation Method Therefor | 1 in force | to Jul 2043 |
| Salt of Pyrrolo[2,3-d]pyrimidine Compound and Novel Polymorph of Salt | 1 in force | to Dec 2035 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,751,889 | Crystalline Form I of Ibrutinib In force · High confidence | In force | High confidence | |
| US 9,957,240 | Crystalline Forms of Trisodium Supramolecular Complex Comprising Valsartan and AHU-377 and Methods Thereof In force · High confidence | In force | High confidence | |
| US 10,508,087 | Crystalline Forms of Trisodium Supramolecular Complex Comprising Valsartan and AHU-377 and Methods Thereof In force · High confidence | In force | High confidence | |
| US 10,138,250 | Salt of Pyrrolo[2,3-d]pyrimidine Compound and Novel Polymorph of Salt In force · High confidence | In force | High confidence | |
| US 10,246,418 | New Crystal Form of Lenvatinib Methanesulfonate Salt and Preparation Method Thereof In force · High confidence | In force | High confidence | |
| US 12,673,955 | New Crystal Form of P-Toluenesulfonate Salt of Diazabicyclic Compound and Preparation Method Therefor In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 2 patents in force now held by others · 17 patents ended · 1 application pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.